EAM
SLRN

Exome Asset Management’s ACELYRIN SLRN Stock Holding History

Exome Asset Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-234,435
Closed -$736K – 79
2024
Q4 		$736K Buy
+234,435
New +$1.14M 0.55% 49

Other funds holding SLRN

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Exome Asset Management's SLRN Position: Q1 2025 in Review

Exome Asset Management sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 234,435 shares — an estimated $736K sold.

Exome Asset Management first reported a position in SLRN in Q4 2024 and held it in 1 quarter. The position peaked at $736K in Q4 2024. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Exome Asset Management reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 234,435 ACELYRIN shares in Q1 2025, an estimated $736K.
  • Exome Asset Management first reported a position in ACELYRIN in Q4 2024 and held it in 1 quarter.
  • Exome Asset Management's ACELYRIN position peaked at $736K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.